Immunotherapy: Open Access
Open Access
ISSN: 2471-9552
+44 1223 790975
ISSN: 2471-9552
+44 1223 790975
Cancer Center Dachau, Germany
Research Article
Rare SARS-CoV-2 Antibody Development in Cancer Patients
Author(s): Louisa Hempel*, Jakob Molnar, Sebastian Robert, Julia Veloso, Zeljka Trepotec, Sofie Englisch, Philip Weinzierl, Cordula Schick, Valeria Milani, Katrin Schweneker, Bastian Fleischmann, Josef Scheiber, Beate Gandorfer, Axel Kleespies, Wolfgang Kaminski, Dirk Hempel, Kristina Riedmann and Armin Piehler
SARS-CoV-2 antibody development and immunity will be crucial for the further course of the pandemic. Until now,
it has been assumed that patients who were infected with SARS-CoV-2 develop antibodies as it is the case with other
coronaviruses, like MERS-CoV and SARS-CoV. In the present study, we analyzed the antibody development of 77
oncology patients 26 days after positive RT-qPCR testing for SARS-CoV2. RT-qPCR and anti-SARS-CoV2-antibody
methods from BGI (MGIEasy Magnetic Beads Virus DNA/RNA Extraction Kit) and Roche (Elecsys Anti-SARS-
CoV-2 immunoassay) were used, respectively, according to the manufacturers’ specifications.
Surprisingly, antibody development was detected in only 6 of 77 individuals with a confirmed history of COVID-19.
Despite of multiple testing, the remaining patients did not show measurable antibody concentrations in subsequent .. View More»